Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Primary listing
Employees
117
Headquarters
Website
NAGE Metrics
BasicAdvanced
$384M
23.90
$0.20
2.23
-
Price and volume
Market cap
$384M
Beta
2.23
52-week high
$14.69
52-week low
$4.72
Average daily volume
1.5M
Financial strength
Current ratio
4.86
Quick ratio
3.734
Long term debt to equity
2.372
Total debt to equity
3.681
Profitability
EBITDA (TTM)
15.081
Gross margin (TTM)
64.28%
Net profit margin (TTM)
13.43%
Operating margin (TTM)
11.05%
Effective tax rate (TTM)
4.45%
Revenue per employee (TTM)
$1,110,000
Management effectiveness
Return on assets (TTM)
10.23%
Return on equity (TTM)
28.35%
Valuation
Price to earnings (TTM)
23.9
Price to revenue (TTM)
2.924
Price to book
4.99
Price to tangible book (TTM)
5.39
Price to free cash flow (TTM)
28.646
Free cash flow yield (TTM)
3.49%
Free cash flow per share (TTM)
0.167
Growth
Revenue change (TTM)
29.95%
Earnings per share change (TTM)
81.82%
3-year revenue growth (CAGR)
21.56%
10-year revenue growth (CAGR)
21.89%
3-year earnings per share growth (CAGR)
-5.90%
10-year earnings per share growth (CAGR)
9.98%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Business Wire·4 days ago
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Business Wire·1 week ago
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $384M as of March 14, 2026.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 23.9 as of March 14, 2026.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of March 14, 2026.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.